Cardinal Health, Inc., a provider of products and services supporting the health care industry, has reached agreement with Eisai Inc. to provide distribution services for Eisai's life-enhancing therapies.

Under terms of the multi-year contract, Cardinal Health will be paid service fees to distribute Eisai's full product line, including Aricept, Aciphex and Zonegran, to hospitals and pharmacies in the US via Cardinal Health's network of 26 distribution centres, a company release informed.

"We are very pleased with the terms of this agreement and more importantly with the fact that our provider customers will continue to have low-cost access to Eisai's important product line," said Mark W. Parrish, chairman and CEO of Pharmaceutical Distribution and Provider Services for Cardinal Health. "We have created a long-term relationship that will improve the efficiency of both companies and serve our customers well, now and into the future. Our goal was to establish a fee-based agreement that provides good value for Eisai and fair compensation for Cardinal Health. With this agreement, both needs have been met with a customized distribution solution that reflects the unique requirements of Eisai's products and the value Cardinal Health provides," he asserted.

Cardinal Health, the company with an annual revenues of more than $65 billion, develops, manufactures, packages and markets products for patient care; develops drug-delivery technologies; distributes pharmaceuticals and medical, surgical and laboratory supplies; and offers consulting and other services that improve quality and efficiency in health care.